After the promulgation of the first edition of expert
consensus on the application of chromosomal microarray analysis (CMA) technology in prenatal diagnosis in 2014, after 8 years of clinical and technical development, CMA technology has become a first-line diagnosis technology for fetal chromosome copy number deletion or duplication abnormalities, and is widely used in the field of prenatal diagnosis in China. However, with the development of the industry and the accumulation of experience in case diagnosis, the application of CMA technology in many important aspects of prenatal diagnosis, such as clinical diagnosis testimony, data analysis and genetic counseling before and after testing, needs to be further standardized and improved, so as to make the application of CMA technology more in line with clinical needs. The revision of the
guideline was led by the National Prenatal Diagnostic Technical Expert Group, and several prenatal diagnostic institutions such as Peking Union Medical College Hospital were commissioned to write, discuss and revise the first draft, which was discussed and reviewed by all the experts of the National Prenatal Diagnostic Technical Expert Group, and was finally formed after extensive review and revision. This
guideline is aimed at the important aspects of the application of CMA technology in prenatal diagnosis and clinical diagnosis, from the clinical application of evidence, test quality control, data analysis and interpretation, diagnosis report writing, genetic counseling before and after testing and other work specifications are elaborated and introduced in detail. It fully reflects the integrated experience, professional thinking and guidance of the current Chinese expert team on the prenatal diagnosis application of CMA technology. The compilation of the
guideline for the application of CMA technology in prenatal diagnosis will strive to promote the standardization and advancement of prenatal diagnosis of fetal chromosome diseases in China.
2014年我国第1版关于染色体微阵列分析(CMA)技术应用于产前诊断的专家共识发布后,经过8年余临床和技术发展的推动,CMA技术目前已经成为针对胎儿的染色体拷贝数缺失或重复异常的一线产前诊断技术,广泛应用于我国产前诊断领域。但随着行业的发展和诊断经验的积累,CMA技术临床应用的许多重要方面,如临床诊断指征、数据分析和检测前后遗传咨询等亟须进一步规范和提升,以使CMA技术的产前诊断应用更加符合临床的需求。本次修订工作由国家卫生健康委员会妇幼健康司批准成立的全国产前诊断专家组牵头,委托北京协和医院等数家产前诊断机构进行初稿的撰写和讨论修订,并经全国产前诊断专家组全体专家进行研讨和审查反馈,以及广泛函审修改后最终形成本指南。本指南针对CMA技术在产前诊断临床应用的重要方面,包括临床应用指征、检测的质量控制、数据的分析解读、诊断报告撰写、检测前后遗传咨询等工作的规范开展进行了详细的阐述和介绍,完整体现了当前中国专家团队对于CMA技术产前诊断应用的经验集成、专业思考和指导意见。本指南的编制将推动全国胎儿染色体及基因组疾病产前诊断工作的规范性和先进性得到进一步的提升。.